No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

No­vo Nordisk’s oral semaglu­tide low­ered the risk of cer­tain heart events in a late-phase study in peo­ple with type 2 di­a­betes and re­lat­ed meta­bol­ic con­di­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER